/
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words allumer French for illuminate and immunis Latin for the immune system.
The business is unprofitable at the operating level (-1886.92% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$370M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$8M
Net Income (TTM)
-$237M
▲ +17.3% YoY
Op. Margin
-5364.02%
ROIC
-75.45%
▲ +32.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$377M
▼ -44.1% YoY
Op. Cash Flow (TTM)
-$376M
▼ -44.9% YoY
Net Debt
-$487M
Net Cash Position
Cash & Equiv.
$523M
Continue Research